GHRL and Parkinson disease: In addition, as AHN undergoes age-related decline and is aberrant in pre-clinical models of neurodegenerative diseases such as Alzheimer’s (Komuro et al., 2015) and Parkinson’s disease (Höglinger et al., 2004), activation of the ghrelin/Ghsr axis may be of therapeutic value in alleviating cognitive decline and promoting healthy ageing.